4D Molecular Therapeutics (FDMT) Cash from Investing Activities (2020 - 2025)
4D Molecular Therapeutics (FDMT) has disclosed Cash from Investing Activities for 6 consecutive years, with -$128.8 million as the latest value for Q4 2025.
- Quarterly Cash from Investing Activities fell 1925.29% to -$128.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$93.0 million through Dec 2025, up 69.26% year-over-year, with the annual reading at -$93.0 million for FY2025, 69.26% up from the prior year.
- Cash from Investing Activities for Q4 2025 was -$128.8 million at 4D Molecular Therapeutics, down from $17.8 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $57.5 million in Q2 2022, with the low at -$263.3 million in Q1 2024.
- Average Cash from Investing Activities over 5 years is -$23.5 million, with a median of -$689500.0 recorded in 2021.
- The sharpest move saw Cash from Investing Activities crashed 39930.95% in 2021, then surged 7897.56% in 2022.
- Over 5 years, Cash from Investing Activities stood at -$32.3 million in 2021, then dropped by 10.8% to -$35.8 million in 2022, then skyrocketed by 81.32% to -$6.7 million in 2023, then surged by 205.64% to $7.1 million in 2024, then tumbled by 1925.29% to -$128.8 million in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$128.8 million, $17.8 million, and -$13.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.